Time

Event

8:00 am –  Lobby

Registration

8:55 am –  2nd Floor

Welcome
* Sara Jane Demy, Founder & CEO, Demy-Colton

9:00 am –  2nd Floor

Fireside Chat
Extending our Health-Span: The Role of Bioelectronic Medicine
In this talk, Dr. Tracey will explore the vagus nerve’s role and how electrical stimulation is revolutionizing treatment for conditions like Rheumatoid arthritis, Crohn’s disease, even cancer, diabetes and mental health conditions. He will offer an insightful look into the current landscape of bioelectronic medicine, highlighting the devices, research, and clinical trials that are paving the way for a future where healthcare relies on computerized devices delivering targeted electrical therapy instead of conventional medications.

Kevin Tracey, President & CEO, Feinstein Institutes for Medical Research at Northwell Health

Interviewed by:
* Jeremy Abbate, Vice President & Publisher, Scientific American
* Sara Jane Demy, Founder & CEO, Demy-Colton

10:00 am –  12th Floor

Dialogue 3A
Bioelectronics: Delivering on the Promise of Neuromodulation for Therapeutic Care
In the decade since the field of bioelectronic medicine emerged as a potential alternative to pharmaceuticals, over $1.5 billion dollars in private capital has been invested in neuromodulation startups. Panelists will share signals of progress at their companies and discuss challenges, trends, and commercial momentum in the field.

Moderator: Naveen Rao, Editor-in-Chief, Neurotech Futures

Panel:
* Manfred Franke, CEO & Co-Founder, Neuronoff
* Yaakov Levine, Vice President, Research, SetPoint Medical
* Ana Maiques, Co-Founder & CEO, Neuroelectrics
* Shri Raghunathan, CEO & Co-Founder, Noctrix Health

10:00 am –  Rooftop

Dialogue 3B
The Fight against Cancer: Where are the Next Transformational Breakthroughs Going to Come From?
How do we move the industry forward to improve cancer patient outcomes and where is this going to come from given the headwinds and challenges facing the field? This panel will discuss where we could be in the next 5-10 years in terms of treatment paradigm and overall patient care/outcomes.

Moderator: Jay Campbell, Managing Director, Cancer Research Institute

Panel:
* Irina Babina, CEO, Concr
* Lynda Chin, Founder, President & CEO, Apricity Health
* Jacob Gottlieb, Managing Partner & Chief Investment Officer, Altium Capital Management
* Daina Graybosch, Senior Managing Director, Biotechnology Analyst, Immuno-Oncology, Leerink Partners

10:00 am –  12th Floor

One-to-One Meetings

11:00 am – 12th Floor

Presenting Companies

12:00 pm –  12th Floor

Dialogue 4A
Tech Innovations of the Future: Deep Tech and AI will Impact Every Aspect of Healthcare
Deep tech and AI are expected to impact almost every aspect of healthcare in the coming years – from predicting the next pandemic, to enabling point of care diagnostics, remote patient monitoring, enhancing drug discovery and other backend systems. This panel of experts will discuss current and new technologies being used in healthcare and the impacts these are expected to have on incumbents and across the healthcare ecosystem.

Moderator: Beth Rogozinski, CEO, Oncoustics

Panel:
* Vinona Bhatia, Founder, P4CI Partnering for Cancer Innovation
* Georgia Ravitz, Partner, FDA & Healthcare Regulatory, Orrick
* Brent Vaughan, Founder, Stealth TechBio

12:00 pm –  Rooftop

Dialogue 4B
The Next Frontier of Obesity Care: The Opportunities and Obstacles Ahead for GLP-1s
This session will explore the evolving obesity care landscape given the rise of GLP-1s and how their use may impact healthcare delivery and economics. The conversation will focus on anticipated changes to care paradigms, as well as potential future health and financial implications due to widespread use of GLP-1s. Join us for an in-depth conversation with a panel of experts on navigating the future of GLP-1s, including the opportunities, trade-offs, risks, and complexities, from market disruptions to healthcare system impact.

Moderator: Sari Kaganoff, Chief Commercial Officer, Rock Health

Panel:
* Dianna Budgeon, SVP, Clinical Operations, knownwell
* Dan Knecht, Chief Clinical Innovation Officer, CVS Caremark
* Sloan Saunders, CEO & Co-Founder, FlyteHealth
* Adam Wolfberg, Chief Medical Officer, Virta Health
* Rich Yang, CEO, Biolinq

1:00 pm –  12th Floor

Luncheon

2:00 pm –  12th Floor

One-to-One Meetings

Presenting Companies

3:30 pm –  12th Floor

Dialogue 5A
Neurodegenerative Disease Funding: Accelerating Scientific Breakthroughs
This panel session will address areas of unmet need and emerging solutions to address neurodegenerative diseases such as Alzheimer’s (AD), Parkinson’s (PD), and Lewy Body Dementia (DLB). We will discuss key industry topics, including investor and pharmaceutical attitudes towards novel therapeutic approaches, the market impact of recent entrants like Leqembi, and sources of optimism and skepticism around investments. The session will also explore creative financial and operational strategies, as well as the role of non-pharmacological solutions like diagnostics, digital tools, and devices in advancing patient care.

Moderator: Joel Sandler, Associate Partner, Ipsos Healthcare Advisory

Panel:
* Karen Harris, CFO & Head, Mission-Related Investing, Alzheimer’s Drug Discovery Foundation (ADDF)
* Christian Howell, CEO, Cognito Therapeutics
* Sean Lorenz, Senior Director, Product Solutions, Altoida

3:30 pm –  Rooftop

Dialogue 5B
Unlocking Longevity: Innovations, Investments, and the Future of Biotech

Moderator: Ed Saltzman, Senior Strategic Advisor, Lumanity

Panel:
* Thomas Ichim, President & CSO, Immorta Bio
* Sergei Petukhov, Founder, Ludicrous Ventures
* Keara Sauber, Managing Director, Sauber Capital
* Robert Schneider, President & Co-Founder, Regerna Therapeutics

4:30 pm –  2nd Floor

End of Day “Big Think" Plenary Session
The Financial Landscape: Are We Coming Out of the Fog? 

Moderator: Stephen Thau, Partner, Co-Head of Life Sciences Practice, Orrick

Panel:
* Jonathan Leff, Partner, Therapeutics, Deerfield, Chairman, Deerfield Institute 
* Art Pappas, CEO & Managing General Partner, Pappas Capital
* Dennis Purcell, Founder, Aisling Capital
* Evonne Sepsis, Founder & Managing Director, ESC Advisors